A phase III trial of Denifanstat for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)
Latest Information Update: 07 Oct 2024
At a glance
- Drugs Denifanstat (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 07 Oct 2024 New trial record
- 01 Oct 2024 According to Sagimet Biosciences Inc. media release, the Company plans to initiate the Phase 3 clinical program for denifanstat in MASH by the end of 2024.